Last reviewed · How we verify
Placebo + Doxycycline
Placebo + Doxycycline is a tetracycline antibiotic Small molecule drug developed by Hospital General de Mexicali. It is currently in Phase 3 development for Acne, Chlamydia, Dermatological infections. Also known as: B.
Doxycycline is a broad-spectrum antibiotic that inhibits protein synthesis in bacteria by binding to the 30S ribosomal subunit.
Doxycycline is a small molecule used in clinical trials for various conditions, including Lateral Epicondylalgia (Tennis Elbow), Cystic Fibrosis, Aneurysm, Acne Vulgaris, and Ocular Rosacea. Placebo is also being studied in clinical trials for these conditions, often in comparison to Doxycycline.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo + Doxycycline |
|---|---|
| Also known as | B |
| Sponsor | Hospital General de Mexicali |
| Drug class | tetracycline antibiotic |
| Target | 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
This inhibition prevents the formation of the 70S initiation complex, thereby blocking the translation of mRNA into proteins. As a result, bacteria are unable to synthesize essential proteins, leading to cell death. Doxycycline is effective against a wide range of bacteria, including those that cause respiratory tract infections, skin infections, and sexually transmitted diseases.
Approved indications
- Acne
- Chlamydia
- Dermatological infections
- Lyme disease
- Mycoplasma pneumoniae infections
- Plague
- Rickettsial infections
- Rosacea
- Skin infections
- Syphilis
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Headache
- Dizziness
- Fatigue
- Skin rash
- Photosensitivity
- Hypersensitivity reactions
Key clinical trials
- A Study of Doxycycline to Treat Chlamydial Infection (PHASE4)
- Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF) (NA)
- FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis (PHASE4)
- Effects of Treatments on Atopic Dermatitis (PHASE2)
- Ocular Rosacea Biome Study (PHASE4)
- the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis (NA)
- Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial) (PHASE2)
- Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo + Doxycycline CI brief — competitive landscape report
- Placebo + Doxycycline updates RSS · CI watch RSS
- Hospital General de Mexicali portfolio CI
Frequently asked questions about Placebo + Doxycycline
What is Placebo + Doxycycline?
How does Placebo + Doxycycline work?
What is Placebo + Doxycycline used for?
Who makes Placebo + Doxycycline?
Is Placebo + Doxycycline also known as anything else?
What drug class is Placebo + Doxycycline in?
What development phase is Placebo + Doxycycline in?
What are the side effects of Placebo + Doxycycline?
What does Placebo + Doxycycline target?
Related
- Drug class: All tetracycline antibiotic drugs
- Target: All drugs targeting 30S ribosomal subunit
- Manufacturer: Hospital General de Mexicali — full pipeline
- Therapeutic area: All drugs in Infectious diseases
- Indication: Drugs for Acne
- Indication: Drugs for Chlamydia
- Indication: Drugs for Dermatological infections
- Also known as: B
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing